FibroGen (FGEN) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
FibroGen Reports Financial Results for the First Quarter of 2016
May 9, 2016 4:02 PM EDTContinued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data
Webcast Conference Call Scheduled for 4:30pm EST Today
SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) (FibroGen), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2016.
We are pleased with the progress of our major development programs across the board, said Thomas B. Neff, chief executive officer of FibroGen. FibroGen and our collaboration partners continue to advance the roxadustat global Phase 3 program in... More
